新闻资讯
- 公司总裁徐卫应邀接受凤…
2月28日上午公司总裁徐卫在公司接到凤凰卫… - 技术入股 ，专利归属谁？…
技术入股，专利归属谁？深圳“伟德国际victor1946”专利… - ASCO公布2013年度临床肿…
ASCO公布2013年度临床肿瘤学进展 “2013年…
Introduction
首页 - About us - Introduction
Sibiono GeneTech Co. Ltd., Shenzhen (Sibiono), is the world's innovator and leader in gene therapy. It was opened at the Shenzhen High-tech Industrial Park in March 1998. In Oct 16, 2003, the innovative product Gendicine®, an adenovirus-based recombinant human p53 for injection (rAd-p53, Inj) was approved by the China Food & Drug Administration (SFDA) with the 'New Drug Certificate’. In Jan 20 and Jan 11. 2004, the 'Production Permit' and 'GMP Recognition' were effected respectively, making it he world's first marketable gene therapy new drug. For many years of hard work in biological gene industry, Sibiono finally made gene therapy clinically available a reality. This is all made possible by years of striving for innovative development, targeting at the promotion of human health.
Sibiono has a strong team of R&D, we took up the responsibility of 'National 973 Project', the 'Tenth 5-year National Major R&D Special Project' and numerous provincial and municipal biotechnological projects. Up to now, our Co. owns 6 invention patents, covering p53 adenovirus injection product itself, its production process, related engineered cells and its application in clinical oncology, basically covering gene therapy and the use of Gendicine®. More than 130 research papers were published in national and international scientific journals. Our Co. initiated the Country's first mass production of recombinant adenovirus-related technology and its quality control platforms, which can also be shared by other recombinant virus products. With the significant collaboration of our Co., we helped affirm the introduction of the 'Guideline for the production of human gene therapy research and quality control of related pharmaceutics'. The Guideline was publicized for application by the SFDA in March 2003, and approved by SFDA for announcement to the international biotechnology community in the journal: 'Biopharm International' in May 2004.
Recently, Sibiono is gradually restructuring our originally research-centered enterprise towards an agglomerate structure of R&D and marketing biopharmaceutical enterprise. With the new planning and development blueprint, we target at building a world class leading biopharmaceuticals, putting emphasis on production, management and series. A scientific panel of Academicians of the Chinese Academy of Sciences was set up. By making use of the existing platforms of experimental gene therapeutics and manufacturing practice with a distribution network, we actively invite potentially competitive gene therapy products under development for further refinement to marketable products. We now have a team of over 1000 specialists employing Gendicine®, in addition to the 300 oncologists from AAA Hospitals on the panel of clinical specialists, who are in charge of further investigation on cancer gene therapy. Our goal-orientated innovative development is coupled with accelerated resource allocations for generating a prominent brand product. We advocate full strength R&D in the extension of cancer treatment application and individualized cancer gene therapy center. We take advantage of the national/ provincial support of the biotechnology industry available to strive for a new round of prosperous development.
Sibiono has a strong team of R&D, we took up the responsibility of 'National 973 Project', the 'Tenth 5-year National Major R&D Special Project' and numerous provincial and municipal biotechnological projects. Up to now, our Co. owns 6 invention patents, covering p53 adenovirus injection product itself, its production process, related engineered cells and its application in clinical oncology, basically covering gene therapy and the use of Gendicine®. More than 130 research papers were published in national and international scientific journals. Our Co. initiated the Country's first mass production of recombinant adenovirus-related technology and its quality control platforms, which can also be shared by other recombinant virus products. With the significant collaboration of our Co., we helped affirm the introduction of the 'Guideline for the production of human gene therapy research and quality control of related pharmaceutics'. The Guideline was publicized for application by the SFDA in March 2003, and approved by SFDA for announcement to the international biotechnology community in the journal: 'Biopharm International' in May 2004.
Recently, Sibiono is gradually restructuring our originally research-centered enterprise towards an agglomerate structure of R&D and marketing biopharmaceutical enterprise. With the new planning and development blueprint, we target at building a world class leading biopharmaceuticals, putting emphasis on production, management and series. A scientific panel of Academicians of the Chinese Academy of Sciences was set up. By making use of the existing platforms of experimental gene therapeutics and manufacturing practice with a distribution network, we actively invite potentially competitive gene therapy products under development for further refinement to marketable products. We now have a team of over 1000 specialists employing Gendicine®, in addition to the 300 oncologists from AAA Hospitals on the panel of clinical specialists, who are in charge of further investigation on cancer gene therapy. Our goal-orientated innovative development is coupled with accelerated resource allocations for generating a prominent brand product. We advocate full strength R&D in the extension of cancer treatment application and individualized cancer gene therapy center. We take advantage of the national/ provincial support of the biotechnology industry available to strive for a new round of prosperous development.
联系伟德国际victor1946
Contact us
地址 ：深圳市高新技术产业园（中区）科技中一路19号
电话：（086）0755-33065208 0755-33065207
邮箱：sbn@hrtoil.com
伟德国际victor1946版权所有 ，并保留所有权利 粤ICP备14054565号-1